A Clinical Isolate of Candida albicans with Mutations in ERG11 (Encoding Sterol 14α-Demethylase) and ERG5 (Encoding C22 Desaturase) Is Cross Resistant to Azoles and Amphotericin B
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
A clinical isolate of Candida albicans was identified as an erg5 (encoding sterol C22 desaturase) mutant in which ergosterol was not detectable and ergosta 5,7-dienol comprised >80% of the total sterol fraction. The mutant isolate (CA108) was resistant to fluconazole, voriconazole, itraconazole, ketoconazole, and clotrimazole (MIC values, 64, 8, 2, 1, and 2 μg ml −1 , respectively); azole resistance could not be fully explained by the activity of multidrug resistance pumps. When susceptibility tests were performed in the presence of a multidrug efflux inhibitor (tacrolimus; FK506), CA108 remained resistant to azole concentrations higher than suggested clinical breakpoints for C. albicans (efflux-inhibited MIC values, 16 and 4 μg ml −1 for fluconazole and voriconazole, respectively). Gene sequencing revealed that CA108 was an erg11 erg5 double mutant harboring a single amino acid substitution (A114S) in sterol 14α-demethylase (Erg11p) and sequence repetition (10 duplicated amino acids), which nullified C22 desaturase (Erg5p) function. Owing to a lack of ergosterol, CA108 was also resistant to amphotericin B (MIC, 2 μg ml −1 ). This constitutes the first report of a C. albicans erg5 mutant isolated from the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Interestingly, the direct target gene of azoles, ERG11 , can only be disrupted in the ERG3 -de fi cient strains or when strains are cultured in media with nystatin or amphotericin B, as the sterols with a C14-methyl group or diols especially for 14-methylergosta-8,24(28)-dien-3 b ,6 a -diol accumulated by ERG3 is lethal in C. albicans .”
From The synthesis, regulation, and functions of sterols in Candida albicans: Well-known but still lots to learn (2016) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“By using the technology of gene disruption and controlled gene expression, ERG1 , ERG7 , ERG9 , ERG25 , ERG26 , and ERG27 have been proved to be essential, while ERG2 , ERG3 , ERG5 , ERG6 , and ERG24 are considered to be non-essential in ergosterol biosynthesis.”
From The synthesis, regulation, and functions of sterols in Candida albicans: Well-known but still lots to learn (2016) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lower abundance of the enzyme has been observed in polyene-resistant species, which has been attributed to mutations in ERG2 [61,112], ERG3 [51], ERG5 [60], ERG6 [113], and ERG11 [60] genes, which encode enzymes involved in ergosterol synthesis.”
From Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens (2018) · cites this paper as [60]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“there is a report of mutations in other ergosterol biosynthesis genes, such as ERG5, conferring azole resistance in C. albicans, this report is isolated.”
From Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans (2020) · cites this paper as [129]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Acquired resistance is also rare, and involves reduced ergosterol biosynthesis and the production of alternative sterols to which amphotericin B has low affinity.”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [64]
Experimental — accuracy not yet measured
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Sanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815 · cited 1×
“There has been an increase in research surrounding the potential importance of drug efflux transporters (26, 30) and changes in sterol 14 -demethylase (ERG11 [CYP51]), the target of azole antifungals (10, 12, 13, 14, 25).”
BackgroundSaville, S. P., Lazzell, A. L., Monteagudo, C., & Lopez-Ribot, J. L. (2003) · Eukaryotic Cell · doi:10.1128/ec.2.5.1053-1060.2003 · Cited by 655 · cited 4×
“(B) Sterol intermediates that accumulate with classical azole inhibition of Erg11p; here, the end product is fungistatic 14 -methyl ergosta 8,24(28)-dien-3 ,6 -diol.”
BackgroundInfluentialWhite, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612 · cited 1×
“Several mechanisms can contribute to azole resistance in pathogenic fungi, such as Candida albicans (4, 11, 14, 32, 33).”
BackgroundSanglard, D., Ischer, F., Koymans, L., & Bille, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.241 · Cited by 465 · cited 2×
“There has been an increase in research surrounding the potential importance of drug efflux transporters (26, 30) and changes in sterol 14 -demethylase (ERG11 [CYP51]), the target of azole antifungals (10, 12, 13, 14, 25).”
BackgroundBaillie, G. S. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.3.397 · Cited by 389 · cited 1×
“Biofilm formation (2) and the possibility for azole sequestration mechanisms (15) have also attracted attention.”
BackgroundKelly, S. L., Lamb, D. C., Kelly, D. E., Manning, N. J., Loeffler, J., Hebart, H., Schumacher, U., & Einsele, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(96)01360-9 · Cited by 351 · cited 2×
“Nonetheless, viable erg3 mutants lacking functional sterol (5,6)-desaturase (encoded by ERG3), and thus ergosterol, have been isolated from the clinic (8, 9, 21).”
BackgroundSelf-citationFranz, R., Kelly, S. L., Lamb, D. C., Kelly, D. E., Ruhnke, M., & Morschhäuser, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.12.3065 · Cited by 339 · cited 1×
“Several mechanisms can contribute to azole resistance in pathogenic fungi, such as Candida albicans (4, 11, 14, 32, 33).”
BackgroundSelf-citationSanguinetti, M., Posteraro, B., Fiori, B., Ranno, S., Torelli, R., & Fadda, G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.668-679.2005 · Cited by 319 · cited 1×
“Values above the suggested clinical breakpoints (27) are in boldface.”
BackgroundWhite, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1488 · Cited by 292 · cited 2×
“Several mechanisms can contribute to azole resistance in pathogenic fungi, such as Candida albicans (4, 11, 14, 32, 33).”
BackgroundLipid Raft Polarization Contributes to Hyphal Growth in Candida albicans
Martin, S. W., & Konopka, J. B. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.3.675-684.2004 · Cited by 232 · cited 1×
“albicans erg3 mutants are reportedly impaired in the ability to form filaments (3, 19), possibly because they lack the ergosterol-rich rafts associated with the leading edge of developing hyphae (17); this does not appear to be true of erg5 mutants.”
BackgroundNolte, F. S., Parkinson, T., Falconer, D. J., Dix, S., Williams, J., Gilmore, C., Geller, R., & Wingard, J. R. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.1.196 · Cited by 219
Watson, P. F., Rose, M. E., Ellis, S. W., England, H., & Kelly, S. L. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)91792-0 · Cited by 197 · cited 1×
“Following the identification of defective sterol (5,6)-desaturase (encoded by ERG3) as a mechanism of azole resistance in Saccharomyces cerevisiae some 20 years ago (31), this mechanism has also been reported in clinical C.”
BackgroundSelf-citationLamb, D. C., Kelly, D. E., Schunck, W.-H., Shyadehi, A. Z., Akhtar, M., Lowe, D. J., Baldwin, B. C., & Kelly, S. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.9.5682 · Cited by 193 · cited 2×
“There has been an increase in research surrounding the potential importance of drug efflux transporters (26, 30) and changes in sterol 14 -demethylase (ERG11 [CYP51]), the target of azole antifungals (10, 12, 13, 14, 25).”
BackgroundSelf-citationDiethylcarbamazine-related antimicrobial activity in Mycobacterium tuberculosis-infected blood
Kitchen, L. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.2.241 · Cited by 183
Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients
Kelly, S. L., Lamb, D. C., Kelly, D. E., Loeffler, J., & Einsele, H. (1996) · The Lancet · doi:10.1016/s0140-6736(05)65949-1 · Cited by 149 · cited 1×
“Nonetheless, viable erg3 mutants lacking functional sterol (5,6)-desaturase (encoded by ERG3), and thus ergosterol, have been isolated from the clinic (8, 9, 21).”
BackgroundSelf-citationKelly, S. L., Lamb, D. C., Baldwin, B. C., Corran, A. J., & Kelly, D. E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.15.9986 · Cited by 145 · cited 2×
“Because the fungistatic sterol 14 -methyl-3,6-diol (1) was not observed to accumulate in CA108 following treatment with fluconazole (Table 1), it was initially reasoned that the mutant Erg5p might function as an azole-binding cytochrome P450 that sequesters free azole away from the target Erg11p (6, 7), thus allowing…”
BackgroundSelf-citationMolecular analysis of cyp51 from fluconazole-resistant Candida albicans strains
Löffler, J., Kelly, S. L., Hebart, H., Schumacher, U., Lass-Flörl, C., & Einsele, H. (2006) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1997.tb12580.x · Cited by 143 · cited 2×
“There has been an increase in research surrounding the potential importance of drug efflux transporters (26, 30) and changes in sterol 14 -demethylase (ERG11 [CYP51]), the target of azole antifungals (10, 12, 13, 14, 25).”
BackgroundSelf-citationPappas, P. G., Chetchotisakd, P., Larsen, R. A., Manosuthi, W., Morris, M. I., Anekthananon, T., Sungkanuparph, S., Supparatpinyo, K., Nolen, T. L., Zimmer, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/599112 · Cited by 141
Miwa, T., Takagi, Y., Shinozaki, M., Yun, C.-W., Schell, W. A., Perfect, J. R., Kumagai, H., & Tamaki, H. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.4.919-931.2004 · Cited by 125 · cited 1×
“It has been postulated (3) that changes in sterol composition may adversely affect membrane-localized components of the signal transduction pathways involved in regulation of cell morphology (18).”
BackgroundMolecular analysis of cyp51 from fluconazole-resistant Candida albicans strains
Löffler, J. (1997) · FEMS Microbiology Letters · doi:10.1016/s0378-1097(97)00172-9 · Cited by 119
Kelly, S. L., Lamb, D. C., Loeffler, J., Einsele, H., & Kelly, D. E. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1136 · Cited by 116 · cited 2×
“There has been an increase in research surrounding the potential importance of drug efflux transporters (26, 30) and changes in sterol 14 -demethylase (ERG11 [CYP51]), the target of azole antifungals (10, 12, 13, 14, 25).”
BackgroundSelf-citationPark, B. J., Arthington-Skaggs, B. A., Hajjeh, R. A., Iqbal, N., Ciblak, M. A., Lee-Yang, W., Hairston, M. D., Phelan, M., Plikaytis, B. D., Sofair, A. N., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1287-1292.2006 · Cited by 113
Molecular aspects of azole antifungal action and resistance
Lamb, D. C., Kelly, D. E., & Kelly, S. L. (1999) · Drug Resistance Updates · doi:10.1054/drup.1999.0112 · Cited by 111 · cited 1×
“Several mechanisms can contribute to azole resistance in pathogenic fungi, such as Candida albicans (4, 11, 14, 32, 33).”
BackgroundSelf-citationAbe, F., Usui, K., & Hiraki, T. (2009) · Biochemistry · doi:10.1021/bi900578y · Cited by 107 · cited 3×
“Because the fungistatic sterol 14 -methyl-3,6-diol (1) was not observed to accumulate in CA108 following treatment with fluconazole (Table 1), it was initially reasoned that the mutant Erg5p might function as an azole-binding cytochrome P450 that sequesters free azole away from the target Erg11p (6, 7), thus allowing…”
BackgroundXu, Y., Chen, L., & Li, C. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn015 · Cited by 104
Sun, S., Li, Y., Guo, Q., Shi, C., Yu, J., & Ma, L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01070-07 · Cited by 102
Lamb, D. C., Kelly, D. E., Waterman, M. R., Stromstedt, M., Rozman, D., & Kelly, S. L. (1999) · Yeast · doi:10.1002/(sici)1097-0061(19990630)15:9<755::aid-yea417>3.0.co;2-8 · Cited by 80
Maesaki, S., Marichal, P., Hossain, M. A., Sanglard, D., Vanden Bossche, H., & Kohno, S. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.6.747 · Cited by 77
Inactivation of Sterol Δ 5,6 -Desaturase Attenuates Virulence in Candida albicans
Chau, A. S., Gurnani, M., Hawkinson, R., Laverdiere, M., Cacciapuoti, A., & McNicholas, P. M. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3646-3651.2005 · Cited by 75
Venkateswarlu, K., Denning, D. W., Manning, N. J., & Kelly, S. L. (1995) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1995.tb07797.x · Cited by 67 · cited 1×
“There has been an increase in research surrounding the potential importance of drug efflux transporters (26, 30) and changes in sterol 14 -demethylase (ERG11 [CYP51]), the target of azole antifungals (10, 12, 13, 14, 25).”
BackgroundSelf-citationMiyazaki, T., Miyazaki, Y., Izumikawa, K., Kakeya, H., Miyakoshi, S., Bennett, J. E., & Kohno, S. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.580-586.2006 · Cited by 49 · cited 1×
“albicans erg3 mutants are reportedly impaired in the ability to form filaments (3, 19), possibly because they lack the ergosterol-rich rafts associated with the leading edge of developing hyphae (17); this does not appear to be true of erg5 mutants.”
BackgroundParker, J. E., Merkamm, M., Manning, N. J., Pompon, D., Kelly, S. L., & Kelly, D. E. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00517-08 · Cited by 46 · cited 2×
“Here, we present information on the phenotypic and genotypic characteristics of a novel azole-resistant strain (CA108) that was initially identified as an erg5 mutant completely lacking ergosterol, using gas chromatography and mass spectrometry (GC/MS) (24).”
MethodSelf-citationSterol 22‐desaturase, cytochrome P45061, possesses activity in xenobiotic metabolism
Kelly, S. L., Lamb, D. C., & Kelly, D. E. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00785-0 · Cited by 42 · cited 10×
“It is possible that fluconazole treatment might have selected for the A114S Erg11p mutation in CA108 with amphotericin B later (or simultaneously) exerting selection pressure toward perturbation or loss of Erg5p activity.”
BackgroundSelf-citationMaebashi, K., Kudoh, M., Nishiyama, Y., Makimura, K., Uchida, K., Mori, T., & Yamaguchi, H. (2002) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2002.tb02702.x · Cited by 37 · cited 1×
“Biofilm formation (2) and the possibility for azole sequestration mechanisms (15) have also attracted attention.”
BackgroundSharma, V., GUPTA, R., Jhingran, A., Singh, B., Sridhara, S., Gaur, S. N., & Arora, N. (2006) · Journal of Clinical Immunology · doi:10.1007/s10875-006-9032-4 · Cited by 25
Wei-su, J. (2006) · Zhonghua weishengwuxue he mianyixue zazhi · Cited by 1
Cited by
Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment
Arendrup, M. C., & Patterson, T. F. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix131 · Cited by 707
Pathogenesis of Candida albicans biofilm
Tsui, C., Kong, E. F., & Jabra-Rizk, M. A. (2016) · Pathogens and Disease · doi:10.1093/femspd/ftw018 · Cited by 481
Emerging Threats in Antifungal-Resistant Fungal Pathogens
Sanglard, D. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00011 · Cited by 416
Biofilm of Candida albicans : formation, regulation and resistance
Pereira, R., Santos Fontenelle, R. O., Brito, E. H. S., & Morais, S. M. (2021) · Journal of Applied Microbiology · doi:10.1111/jam.14949 · Cited by 368
Metadata
- Authors
- Martel, C. M., Parker, J. E., Bader, O., Weig, M., Gross, U., Warrilow, A. G. S., Kelly, D. E., & Kelly, S. L.
- Affiliations
- Swansea University (GB)
- Universitätsmedizin Göttingen (DE)
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2010-09
- Volume
- 54
- Issue
- 9
- Pages
- 3578-3583
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC2934972
- OpenAlex
- W2162351832
- Cited by
- 165
- References
- 37
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 14 · 2023: 14 · 2022: 9 · 2021: 12 · 2020: 10 · 2019: 18 · 2018: 15 · 2017: 10 · 2016: 9 · 2015: 6 · 2014: 11 · 2013: 6 · 2012: 7
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- GRO (submittedVersion, cc-by)
- Funders
- Engineering and Physical Sciences Research Council
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida albicans, azole resistance, amphotericin B resistance, ERG11, sterol 14α-demethylase, fluconazole, voriconazole, ketoconazole, clotrimazole, itraconazole, multidrug efflux pumps, tacrolimus, FK506, clinical isolates, double mutants
- MeSH terms
- Amphotericin B, Antifungal Agents, Azoles, Candida albicans, Fungal Proteins, Microbial Sensitivity Tests, Mutation, Polymerase Chain Reaction, Drug Resistance, Fungal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.